BioSpace News Archive

Data to Support MindMed’s Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders

Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski , CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same capacity for VIATRIS TM (“Viatris”). At Viatris, Szablewski will be responsible for

Approvals received from Bpifrance and SociétéGénéralefor a total of EUR 10 million in non-dilutive financing in the form of a State-Guaranteed Loan (PGE Loan)

Ultimovacs ASA, announced the acceptance of publication in Frontiers in Immunology, outlining the positive long-term follow-up data from the company’s Phase I trial evaluating its proprietary universal cancer vaccine, UV1, in non-small cell lung cancer.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that management will present at the following upcoming investor relations events.

Athos Therapeutics Inc., a late pre-clinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, announced the appointment of Keith Bronson Hoffman, Ph.D. as their Chief Business Officer.

Highly diverse samples will enable development of world’s first 3D genomics prognostic immune health test for disease severity

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced its Founder and CEO, Maria Maccecchini, Ph.D., is presenting at the Meridian Clinical Trials Summit on November 2, 2020 at 10 a.m. ET.

VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.

Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share